The FDA issued warning letters to 30 telehealth companies over misleading claims about compounded versions of popular ...

Clinical trials and equitable care pathways are needed to build on early evidence of benefit Substance use disorders (SUDs) ...

People struggling with many addictions, ranging from opioids to gambling, are reporting similar experiences in clinics, on ...

Researchers at Washington University School of Medicine in St. Louis show in a new study that GLP-1 medications may be ...

The FDA requested that manufacturers of GLP-1 receptor agonists remove information regarding risks of suicidal behavior and ideation from drug labels following a detailed review of existing data, the ...

Since 2021, the story of GLP-1s has illustrated that scientific progress is rarely a straight line from hypothesis to patient ...

Research suggests the drugs have potential for prevention and harm reduction in substance use disorders, writes Ziyad Al-Aly People taking glucagon-like peptide-1 (GLP-1) receptor agonists often ...

At a White House event Thursday, President Trump announced deals with drugmakers Novo Nordisk and Eli Lilly to offer their popular GLP-1 obesity and diabetes drugs at lower prices for some Americans, ...

Phenomix's MyPhenome test continues to demonstrate predictive accuracy in identifying which patients are most likely to respond to GLP-1 therapies such as semaglutide. Studies presented at Obesity ...

A November 2025 Kaiser Family Foundation poll found that 1 in 8 U.S. adults have tried a GLP-1 medication for weight loss, diabetes or another condition. And we expect that number to rise now that one ...

Rachel Brophy is no fan of President Trump, but she said he did something this week that will ease a little of the financial pain she expects to start feeling next year. Brophy, a 38-year-old ...

Who controls the narrative, where the money is going, and why patients need to be at the centre of what comes next News ...